These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36379889)

  • 21. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
    Satgunaseelan L; Gupta R; Madore J; Chia N; Lum T; Palme CE; Boyer M; Scolyer RA; Clark JR
    Pathology; 2016 Oct; 48(6):574-80. PubMed ID: 27590194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
    Okada S; Itoh K; Ishihara S; Shimada J; Kato D; Tsunezuka H; Miyata N; Hirano S; Teramukai S; Inoue M
    Surg Oncol; 2018 Jun; 27(2):259-265. PubMed ID: 29937180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 expression in fine-needle aspiration cell blocks of head and neck squamous-cell carcinoma and its cytohistological concordance.
    Lou SSK; Ruff H; MacDonald S; Smith SM; Cheung CC
    Diagn Cytopathol; 2024 Mar; 52(3):163-170. PubMed ID: 38095142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
    Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
    Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of PD-L1 IHC 22C3 PharmDx Combined Positive Score (CPS) in Primary Versus Metastatic Nodal Squamous Cell Carcinomas of the Head and Neck: Is There a Significant Difference?
    Surucu A; Hou T; Kuhar M; Durm G; Mesa H
    Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):550-554. PubMed ID: 37358840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
    Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
    Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.
    Chang SR; Chou CH; Liu CJ; Lin YC; Tu HF; Chang KW; Lin SC
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
    Roper E; Lum T; Palme CE; Ashford B; Ch'ng S; Ranson M; Boyer M; Clark J; Gupta R
    Pathology; 2017 Aug; 49(5):499-505. PubMed ID: 28666643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
    Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
    Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
    He J; Chen XF; Xu MG; Zhao J
    Arch Oral Biol; 2020 Jun; 114():104717. PubMed ID: 32344357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside.
    Nocini R; Vianini M; Girolami I; Calabrese L; Scarpa A; Martini M; Morbini P; Marletta S; Brunelli M; Molteni G; Parwani A; Pantanowitz L; Eccher A
    Clin Exp Dent Res; 2022 Jun; 8(3):690-698. PubMed ID: 35593124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of PD-L1 and PD-1 in stage T4 rectal cancer tissues and surrounding metastatic lymph nodes and correlation with prognosis.
    Wang Y; Lu H; Li M
    Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):74-78. PubMed ID: 36800834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Considerable interlaboratory variation in PD-L1 positivity for head and neck squamous cell carcinoma in the Netherlands- A nationwide evaluation study.
    Hempenius MA; Koomen BM; Deckers IAG; Oosting SF; Willems SM; van der Vegt B
    Histopathology; 2024 Jul; 85(1):133-142. PubMed ID: 38606992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
    Schneider S; Kadletz L; Wiebringhaus R; Kenner L; Selzer E; Füreder T; Rajky O; Berghoff AS; Preusser M; Heiduschka G
    Histopathology; 2018 Oct; 73(4):573-584. PubMed ID: 29742291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interobserver Agreement on the Interpretation of Programmed Death-ligand 1 (PD-L1) Combined Positive Score (CPS) Among Gynecologic Pathologists.
    Mills AM; Bennett JA; Banet N; Watkins JC; Kundu D; Pinto A
    Am J Surg Pathol; 2023 Aug; 47(8):889-896. PubMed ID: 37272261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma.
    Scognamiglio T; Chen YT
    Head Neck Pathol; 2018 Jun; 12(2):221-229. PubMed ID: 28948509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
    Heeren AM; Punt S; Bleeker MC; Gaarenstroom KN; van der Velden J; Kenter GG; de Gruijl TD; Jordanova ES
    Mod Pathol; 2016 Jul; 29(7):753-63. PubMed ID: 27056074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of PD-1 and PD-L1 expression in oral leukoplakia and oral squamous cell carcinoma: an immunohistochemical study.
    Greeshma LR; Joseph AP; Sivakumar TT; Raghavan Pillai V; Vijayakumar G
    Sci Rep; 2023 Dec; 13(1):21698. PubMed ID: 38066025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy.
    Paolino G; Pantanowitz L; Barresi V; Pagni F; Munari E; Moretta L; Brunelli M; Bariani E; Vigliar E; Pisapia P; Malapelle U; Troncone G; Girolami I; Eccher A
    Pathol Res Pract; 2021 Oct; 226():153605. PubMed ID: 34530257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of the PD-L1 expression, T-cells density and immunoscore in paired baseline tumor biopsies and surgical specimens in squamous cell carcinoma of the oral cavity.
    Beyaert S; Borys A; Baldin P; Dahou H; Magremanne M; Mahy P; Renwart W; Machiels JP; Schmitz S
    Oral Oncol; 2024 Jul; 154():106869. PubMed ID: 38820890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.